The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca.

This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADCs are designed for targeting cancer cells specifically and selectively provide a highly potent payload that may limit healthy cells’ damage.

An ADC includes a monoclonal antibody, which helps recognise a protein that is present in the cancer cells and is bound to the payload, a cytotoxic agent.

ADCs are currently in early-phase trials in non-small cell lung cancer, with promising results.

The new research partnership seeks to support research to study TROP2-directed and HER2-directed ADCs including biomarkers, mechanism of action and resistance mechanisms.

LCRF Scientific Advisory Board chair Katerina Politi said: “LCRF is honoured to continue its long legacy of identifying and supporting outstanding lung cancer research projects over the years. We are excited to collaborate with these generous supporters of our mission.

“The specific focus of this grant programme is to further study ADCs and how they might be applied to lung cancer treatment. It is an exciting and promising area in lung cancer research.”

The LCRF – Daiichi SankyoAstraZeneca Research Grant on ADCs will be used to develop further understanding of the mechanism of action and biomarkers for HER2-directed ADCs in HER2 mutant NSCLC and TROP2-directed ADCs in lung cancer, as well as primary and acquired resistance to HER2 directed and TROP2 directed ADCs.

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.